Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

Chandra P. Belani; Jose R. Pereira; Joachim von Pawel; Anna Pluzanska; Vera Gorbounova; Eckhard Kaukel; Karin V. Mattson; Rodryg Ramlau; Aleksandra Szczesna; Panos Fidias; Michael Millward; Frank Fossella

doi:10.1016/j.lungcan.2006.05.003

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

Chandra P. Belani, Jose R. Pereira, Joachim von Pawel, Anna Pluzanska, Vera Gorbounova, Eckhard Kaukel, Karin V. Mattson, Rodryg Ramlau, Aleksandra Szczesna, Panos Fidias, Michael Millward, Frank Fossella

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m² plus cisplatin 75 mg/m², every 3 weeks (DC); docetaxel 75 mg/m² and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m²/week plus cisplatin 100 mg/m², every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.

Original language	English (US)
Pages (from-to)	231-239
Number of pages	9
Journal	Lung Cancer
Volume	53
Issue number	2
DOIs	https://doi.org/10.1016/j.lungcan.2006.05.003
State	Published - Aug 2006

Keywords

Advanced non-small cell lung cancer
Carboplatin
Cisplatin
Docetaxel
Patient-reported outcomes
Quality of life
Symptoms
Vinorelbine

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.1016/j.lungcan.2006.05.003

Cite this

Belani, C. P., Pereira, J. R., von Pawel, J., Pluzanska, A., Gorbounova, V., Kaukel, E., Mattson, K. V., Ramlau, R., Szczesna, A., Fidias, P., Millward, M., & Fossella, F. (2006). Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer, 53(2), 231-239. https://doi.org/10.1016/j.lungcan.2006.05.003

Belani, CP, Pereira, JR, von Pawel, J, Pluzanska, A, Gorbounova, V, Kaukel, E, Mattson, KV, Ramlau, R, Szczesna, A, Fidias, P, Millward, M & Fossella, F 2006, 'Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial', Lung Cancer, vol. 53, no. 2, pp. 231-239. https://doi.org/10.1016/j.lungcan.2006.05.003

@article{db04335636294a52abaefefb2671ce43,

title = "Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial",

abstract = "Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-na{\"i}ve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item {"}QoL today{"}: P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item {"}health state today{"}: P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS {"}QoL today{"}, which was not significant.",

keywords = "Advanced non-small cell lung cancer, Carboplatin, Cisplatin, Docetaxel, Patient-reported outcomes, Quality of life, Symptoms, Vinorelbine",

author = "Belani, {Chandra P.} and Pereira, {Jose R.} and {von Pawel}, Joachim and Anna Pluzanska and Vera Gorbounova and Eckhard Kaukel and Mattson, {Karin V.} and Rodryg Ramlau and Aleksandra Szczesna and Panos Fidias and Michael Millward and Frank Fossella",

note = "Funding Information: We are indebted to Francis C. Gamza, MD, Jocelyne Berille, MD, and Yong S. Kim, PhD (statistician) for planning and implementing the study; Antoinette Wozniak, MD, Lionel Bosquee, MD, and Claude Ramazeilles, PhD for their valuable insights; Luz Hammershaimb, MD, Antoine Yver, MD, and Jean-Pierre Bizzari, MD for their support of the study; Richard Gralla, MD for assistance with data analyses; Mark R. Green, MD (Chair), Lucio Crino, MD, and Boris Iglewicz, PhD from the independent data monitoring committee; to Wendy Crist (international study manager), Isabelle Dancy, PhD (study manager), Anthony Rodgers, PhD (statistician), Martin Roessner, MSc (statistician), James Stephens (statistician), Sandrine Anneheim-Herbelin, PhD (study manager), and Jean-Luc Schmidt (data manager). All authors confirm that they have not received payment for writing this article. The study was funded by Aventis Pharmaceuticals, a member of the sanofi-aventis Group. The sponsor provided assistance with study management, data collection, statistical analysis, and editorial support.",

year = "2006",

month = aug,

doi = "10.1016/j.lungcan.2006.05.003",

language = "English (US)",

volume = "53",

pages = "231--239",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

AU - Belani, Chandra P.

AU - Pereira, Jose R.

AU - von Pawel, Joachim

AU - Pluzanska, Anna

AU - Gorbounova, Vera

AU - Kaukel, Eckhard

AU - Mattson, Karin V.

AU - Ramlau, Rodryg

AU - Szczesna, Aleksandra

AU - Fidias, Panos

AU - Millward, Michael

AU - Fossella, Frank

N1 - Funding Information: We are indebted to Francis C. Gamza, MD, Jocelyne Berille, MD, and Yong S. Kim, PhD (statistician) for planning and implementing the study; Antoinette Wozniak, MD, Lionel Bosquee, MD, and Claude Ramazeilles, PhD for their valuable insights; Luz Hammershaimb, MD, Antoine Yver, MD, and Jean-Pierre Bizzari, MD for their support of the study; Richard Gralla, MD for assistance with data analyses; Mark R. Green, MD (Chair), Lucio Crino, MD, and Boris Iglewicz, PhD from the independent data monitoring committee; to Wendy Crist (international study manager), Isabelle Dancy, PhD (study manager), Anthony Rodgers, PhD (statistician), Martin Roessner, MSc (statistician), James Stephens (statistician), Sandrine Anneheim-Herbelin, PhD (study manager), and Jean-Luc Schmidt (data manager). All authors confirm that they have not received payment for writing this article. The study was funded by Aventis Pharmaceuticals, a member of the sanofi-aventis Group. The sponsor provided assistance with study management, data collection, statistical analysis, and editorial support.

PY - 2006/8

Y1 - 2006/8

N2 - Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.

AB - Background: Patients with advanced non-small cell lung cancer (NSCLC) do not have curative treatment options; therefore, treatments should prolong survival and improve quality of life (QoL). We compared the effect on QoL of two docetaxel-platinum regimens with vinorelbine-cisplatin. Methods: QoL was assessed by the Lung Cancer Symptom Scale (LCSS) and the general EuroQol five-dimensional questionnaire (EQ-5D) in 926 chemotherapy-naïve patients with stages IIIB to IV NSCLC. Patients were randomly assigned to receive: docetaxel 75 mg/m2 plus cisplatin 75 mg/m2, every 3 weeks (DC); docetaxel 75 mg/m2 and carboplatin 6 mg/ml min, every 3 weeks (DCb); or vinorelbine 25 mg/m2/week plus cisplatin 100 mg/m2, every 4 weeks (VC). Results: Overall, patients treated with either docetaxel-containing regimen had better QoL than VC-treated patients (LCSS global item "QoL today": P = 0.064 for DC and P = 0.016 for DCb versus VC; EQ-5D global item "health state today": P = 0.016 for DC and P < 0.001 for DCb versus VC). DC-treated patients experienced improved pain relief compared with VC (P = 0.033), whereas pain relief with DCb and VC was similar. Patients treated with either docetaxel regimen had more favorable changes in performance status (P = 0.065 for DC and P < 0.001 for DCb versus VC) and mean weight loss (0.06 kg, gain of 0.08 kg, and 2.27 kg for DC, DCb, and VC, respectively; P < 0.001 for both DC versus VC and DCb versus VC). Conclusion: The TAX 326 study shows that docetaxel-platinum regimens relieve symptoms and improve QoL in patients with advanced NSCLC. DCb and DC were superior to VC in all QoL outcomes assessed except for the difference between DC and VC in LCSS "QoL today", which was not significant.

KW - Advanced non-small cell lung cancer

KW - Carboplatin

KW - Cisplatin

KW - Docetaxel

KW - Patient-reported outcomes

KW - Quality of life

KW - Symptoms

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=33745893529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745893529&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2006.05.003

DO - 10.1016/j.lungcan.2006.05.003

M3 - Article

C2 - 16787687

AN - SCOPUS:33745893529

SN - 0169-5002

VL - 53

SP - 231

EP - 239

JO - Lung Cancer

JF - Lung Cancer

IS - 2

ER -

Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this